To: IMPAACT Principal Investigators and Study Coordinators at Sites Participating in IMPAACT P1094

From: IMPAACT P1094 Protocol Team

Date: March 19, 2012

Re: Clarification Memo #1 for Protocol IMPAACT P1094, Version 2.0, dated March 07, 2012, entitled “Evaluation of 3TC or FTC Monotherapy Compared to Continuing HAART as a Bridging Antiretroviral Strategy inPersistently Non-adherent Children, Adolescents, and Young Adults who are Failing HAART and have the M184V Resistance Mutation”

This is Clarification Memo #1 for IMPAACT P1094, Version 2.0, dated March 07, 2012. This Memo can be obtained from the P1094 Protocol Specific Webpage (https://impaactgroup.org/). Enter the Member/MIS area using your individual username and password. Search for the study number. From the P1094 web page you will have the option to click the PSWP tab.

This memo serves to clarify the following:

The correct date of the protocol is March 07, 2012. The dates indicated after the protocol title on page 11 under the heading ‘Summary of Changes’ and on page 1 of the Sample Informed Consent Form are typographical errors. Site specific informed consent forms should indicate the date as March 07, 2012

The correct listing for the NIAID Medical Officer on the title page and in the team roster on page 2 is Hans M.L. Spiegel, M.D., DTMH, Contractor.
          Medical Officer, HJF-DAIDS, NIAID, NIH

Please contact the protocol team at impaact.teamp1094@fstrf.org if you have any questions. Thank you for your interest in IMPAACT P1094.

Sincerely,

The P1094 Protocol Team